Humanigen: Rises on publication of data from COVID-19 treatment trial

Humanigen

05/05/2021 17:33

** Drug developer's shares  HGEN.O  rise as much as 5% to
$19 
    ** Co announces publication of results from late-stage trial
of its lead drug candidate, Lenzilumab, to treat hospitalized
COVID-19 patients  urn:newsml:reuters.com:*:nBw6SMpjHa
    ** In March, co said patients getting the drug along with
steroids and Gilead Inc's  GILD.O  antiviral remdesivir are 54%
more likely to survive without mechanical ventilation vs
patients on placebo  urn:newsml:reuters.com:*:nL4N2LR2FR
    ** HGEN's stock was weak earlier this week on concerns that
co had not received emergency use authorization (EUA) yet for
lenzilumab - Cantor Fitzgerald analyst Louise Chen 
    ** The results of this study should increase HGEN's chances
for getting an EUA - Chen 
    ** If EUA is granted, Chen expects sales of ~$1 bln 12
months post launch
    ** Stock is up ~8% YTD

 (Reporting by Dania Nadeem in Bengaluru)
 ((Dania.Nadeem@thomsonreuters.com;))